Evidence map›Paper›PMID 36139642›Full record

ArticleCancers2022

MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells.

Renier C Heijkants, Amina F A S Teunisse, Danielle de Jong, Kseniya Glinkina, Hailiang Mei, Szymon M Kielbasa, Karoly Szuhai, Aart G Jochemsen

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.International journal of biological sciences · 2025
    Article
  5. Review
  6. Article
  7. Design, Synthesis, andAnti-cancer agents in medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Renier C HeijkantsDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Amina F A S TeunisseDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Danielle de JongDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Kseniya GlinkinaDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0002-4436-3917
Hailiang MeiSequencing Analysis Support Core, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0003-1781-5508
Szymon M KielbasaSequencing Analysis Support Core, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Karoly SzuhaiDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0002-1228-4245
Aart G JochemsenDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Leiden University Medical Center · NL

Funding

Dutch Cancer Society UL 2013-5757European Union 667787
6 · The paper itself

Abstract

The tumor suppressor protein p53 has an important role in cell-fate determination. In cancer cells, the activity of p53 is frequently repressed by high levels of MDMX and/or MDM2. MDM2 is a ubiquitin ligase whose activity results in ubiquitin- and proteasome-dependent p53 degradation, while MDMX inhibits p53-activated transcription by shielding the p53 transactivation domain. Interestingly, the oncogenic functions of MDMX appear to be more wide-spread than inhibition of p53. The present study aimed to elucidate the MDMX-controlled transcriptome. Therefore, we depleted MDMX with four distinct shRNAs from a high MDMX expressing uveal melanoma cell line and determined the effect on the transcriptome by RNAseq. Biological function analyses indicate the inhibition of the cell cycle regulatory genes and stimulation of cell death activating genes upon MDMX depletion. Although the inhibition of p53 activity clearly contributes to the transcription regulation controlled by MDMX, it appeared that the transcriptional regulation of multiple genes did not only rely on p53 expression. Analysis of gene regulatory networks indicated a role for Forkhead box (FOX) transcription factors. Depletion of FOXO proteins partly prevented the transcriptional changes upon MDMX depletion. Furthermore, depletion of FOXO proteins relatively diminished the growth inhibition upon MDMX knockdown, although the knockdown of the FOXO transcription factors also reduces cell growth. In conclusion, the p53-independent oncogenic functions of MDMX could be partially explained by its regulation of FOXO activity.

Indexed as

cutaneous melanomaFOXOMDM2MDMXp53RFX7RNA-sequveal melanoma

Identifiers

PMID36139642
PMCPMC9496676
OpenAlexW4296106945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.